Status:
RECRUITING
Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study
Lead Sponsor:
Centers for Medicare and Medicaid Services/ Coverage and Analysis Group
Conditions:
Mild Alzheimer's Disease
Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
Eligibility:
All Genders
Brief Summary
The Anti-Aβ mAb CED Study is a prospective, longitudinal coverage with evidence development (CED) study using clinical data, patient assessments, and administrative claims data of the Medicare populat...
Detailed Description
The Anti-Aβ mAb CED Study is conducted in accordance with the coverage criteria specified in the NCD for patients who have a clinical diagnosis of mild cognitive impairment (MCI) due to AD or mild AD ...
Eligibility Criteria
Inclusion
- Medicare patients with a clinical diagnosis of mild cognitive impairment due to Alzheimer's disease (AD) or mild AD dementia, both with confirmed presence of amyloid beta pathology consistent with AD.
Exclusion
- none
Key Trial Info
Start Date :
July 6 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2029
Estimated Enrollment :
8680 Patients enrolled
Trial Details
Trial ID
NCT06058234
Start Date
July 6 2023
End Date
June 30 2029
Last Update
September 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centers for Medicare and Medicaid Services
Baltimore, Maryland, United States, 21244